Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma

Steven Aller, Andrada Roxana Popescu, Sudha Rao, Elaine R Morgan, Yasmin C Gosiengfiao*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC.

Original languageEnglish (US)
Pages (from-to)98-100
Number of pages3
JournalPediatric Blood and Cancer
Volume58
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Pediatrics
Therapeutics
sorafenib
Medullary Thyroid cancer
Research
Neoplasms

Keywords

  • MEN2B syndrome
  • Metastatic medullary thyroid carcinoma
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

@article{49483f68056142eea4ed7a0cd80099c2,
title = "Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma",
abstract = "Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC.",
keywords = "MEN2B syndrome, Metastatic medullary thyroid carcinoma, Sorafenib",
author = "Steven Aller and Popescu, {Andrada Roxana} and Sudha Rao and Morgan, {Elaine R} and Gosiengfiao, {Yasmin C}",
year = "2012",
month = "1",
day = "1",
doi = "10.1002/pbc.23032",
language = "English (US)",
volume = "58",
pages = "98--100",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma

AU - Aller, Steven

AU - Popescu, Andrada Roxana

AU - Rao, Sudha

AU - Morgan, Elaine R

AU - Gosiengfiao, Yasmin C

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC.

AB - Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC.

KW - MEN2B syndrome

KW - Metastatic medullary thyroid carcinoma

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=81155144841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155144841&partnerID=8YFLogxK

U2 - 10.1002/pbc.23032

DO - 10.1002/pbc.23032

M3 - Article

VL - 58

SP - 98

EP - 100

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -